Your session is about to expire
← Back to Search
Dasatinib for Chronic Myeloid Leukemia
Study Summary
This trial studies dasatinib for early chronic phase chronic myelogenous leukemia. Dasatinib may stop cancer cell growth by blocking enzymes needed for cell growth.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I don't have recent severe chest pain, heart rhythm problems, very high blood pressure, or a history of significant bleeding disorders.I can care for myself and perform daily activities.My condition has evolved but hasn't reached an accelerated phase.I am using two effective birth control methods and have a negative pregnancy test.My chronic myeloid leukemia is not in the late, accelerated, or blast phase.I was diagnosed with early-stage CML less than a year ago and have had little to no treatment.My liver and kidney functions are within normal limits.My heart condition severely limits my daily activities.I am 16 years or older.
- Group 1: Arm B (twice daily dasatinib)
- Group 2: Arm A (once daily dasatinib)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the maximum capacity of enrollees for this experiment?
"Presently, this study is not seeking any more participants. It was initially registered on November 8th 2005 and updated most recently on May 31st 2022. If you are looking for alternative trials, there are currently 1455 studies actively recruiting patients diagnosed with leukemia, myeloid chronic-phase and 64 Pharmacological Studies that require volunteers."
Has the Pharmacological Study been sanctioned by the Federal Drug Administration?
"In consideration of the Phase 2 status, our team at Power assigned a safety rating of 2 to this pharmacological study. This is due to existing evidence for its security but not yet any proof that it produces desirable outcomes."
Have any other investigations sought to explore the efficacy of this Pharmacological Study?
"Presently, 64 clinical trials are researching treatments related to Pharmacological Study. Of those active investigations, 9 have advanced to Phase 3 of the research process. Although most studies on this treatment occur in New york City, there are 4258 sites conducting these experiments worldwide."
Is this investigation actively seeking participants?
"Per the clinicaltrials.gov listing, this research project is not currently accepting new participants. The trial began on November 8th 2005 and was last modified May 31st 2022. However, there are 1519 other studies still open to enrollment at this moment in time."
Share this study with friends
Copy Link
Messenger